Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole

By Potkin Steven G.   Raoufinia Arash   Mallikaarjun Suresh   Bricmont Patricia   Peters-Strickland Timothy   Kasper William   Baker Ross A.   Eramo Anna   Sanchez Raymond   McQuade Robert  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1241-1251

Informa Healthcare

Access to resources Recommend Favorite

One‐year follow‐up of a TRASER clinical trial for the treatment of nasal telangiectasias

By  

LASERS IN SURGERY AND MEDICINE, Vol. 50, Iss. 1, 2018-01 ,pp. : 61-63

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic

By Einarson Thomas R.   Zilbershtein Roman   Skoupá Jana   Veselá Šárka   Garg Madhur   Hemels Michiel E. H.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1089-1095

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective

By Altamura A.C.   Armadoros D.   Jaeger M.   Kernish R.   Locklear J.   Volz H.-P.  

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2271-2282

Informa Healthcare

Access to resources Recommend Favorite